UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 19, 2019

 


 

RHYTHM PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 


 

Delaware

 

001-38223

 

46-2159271

(State or other jurisdiction
of incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification Number)

 

222 Berkeley Street

12th Floor

Boston, MA  02116

(Address of principal executive offices, including Zip Code)

 

Registrant’s telephone number, including area code: (857) 264-4280

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  x

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

RYTM

 

The Nasdaq Stock Market LLC (Nasdaq Global Market)

 

 

 


 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

(a)           Rhythm Pharmaceuticals, Inc. (the “Company”) held its 2019 Annual Meeting of Stockholders (the “Annual Meeting”) on June 19, 2019.

 

(b)           The final voting results on each of the matters submitted to a vote of stockholders at the Annual Meeting are set forth below.

 

(1) The following director nominees were elected to serve as Class II directors until the Company’s 2022 Annual Meeting of Stockholders and until their successors are duly elected and qualified:

 

Nominee

 

Votes For

 

Votes Withheld

 

Votes Abstaining

 

Broker Non-Votes

 

Jennifer Good 

 

28,033,908

 

4,538

 

36,100

 

2,720,748

 

Todd Foley

 

24,084,965

 

19,553

 

3,970,028

 

2,720,748

 

Ed Mathers

 

21,664,321

 

2,177,752

 

4,232,473

 

2,720,748

 

 

(2) The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019 was ratified.

 

Votes For

 

Votes Against

 

Votes Abstaining

 

30,764,774

 

1,375

 

29,145

 

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

RHYTHM PHARMACEUTICALS, INC.

 

 

 

Date: June 21, 2019

By:

/s/ Hunter Smith

 

 

Hunter Smith

 

 

Chief Financial Officer

 

3